| Literature DB >> 30586432 |
Dominick M Raphael1, Laurine Roos2, Victor Myovela1, Elisante Mchomvu1, Jabir Namamba1, Said Kilindimo3, Winfrid Gingo1, Christoph Hatz2,4, Daniel H Paris2,4, Maja Weisser2,4,5,6, Richard Kobza7, Martin Rohacek1,2,4,5.
Abstract
BACKGROUND: Little is known about heart diseases and their treatment in rural sub-Saharan Africa. This study aimed to describe the occurrence, characteristics, and etiologies of heart diseases, and the medication taken before and prescribed after echocardiography in a rural referral Hospital in Tanzania.Entities:
Mesh:
Year: 2018 PMID: 30586432 PMCID: PMC6306243 DOI: 10.1371/journal.pone.0208931
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics.
| Patient characteristics | Adults (n = 815) | Children (n = 59) |
|---|---|---|
| Age [years], median (range) | 59 (16–98) | 5 (0.003–15) |
| Children <5 years, n (%) | N/A | 28 (47%) |
| Male sex, n (%) | 329 (40%) | 27 (46%) |
| Weight [kg] (n = 793)/(n = 55), median (range) | 60 (30–150) | 16 (2–43) |
| Height [cm] (n = 793)/(n = 51), median (range) | 160 (103–190) | 106 (50–162) |
| BSA [m2] (n = 793)/(n = 51), median (range) | 1.62 (1.1–2.66) | 0.7 (0.22–1.41) |
| BMI [kg/m2] (n = 793)/(n = 51), median (range) | 23.19 (13.16–57.85) | N/A |
| Underweight (n = 793)/(n = 51), n (%) | 86 (11%) | 17 (33%) |
| Normal weight (n = 793)/(n = 51), n (%) | 425 (54%) | 28 (55%) |
| Overweight (n = 793)/(n = 51), n (%) | 165 (21%) | 5 (10%) |
| Obesity (n = 793)/(n = 51), n (%) | 117 (15%) | 1 (2%) |
| Hypertension, n (%) | 537 (66%) | 2 (3%) |
| Stroke, n (%) | 53 (7%) | 0 (0%) |
| Pregnancy in the last 6 months, n (%) | 68 (8%) | 0 (0%) |
| No medication before presentation, n (%) | 506 (62%) | 44 (75%) |
| Inpatient, n (%) | 178 (22%) | 21 (36%) |
| HIV positive, n (%) | 41 (5%) | 0 (0%) |
| Dyspnoea, n (%) | 485 (60%) | 32 (54%) |
| Orthopnoea, n (%) | 398 (49%) | 19 (32%) |
| Chest pain, n (%) | 230 (28%) | 8 (14%) |
| Systolic BP [mmHg] (n = 806)/(n = 23), median (range) | 140 (70–260) | 115 (80–165) |
| Diastolic BP [mmHg] (n = 806)/(n = 23), median (range) | 80 (30–150) | 70 (40–120) |
| HR [beat/min] (n = 764)/(n = 44), median (range) | 80 (36–160) | 110 (70–200) |
| Irregular heartbeat, n (%) | 118 (14%) | 3 (5%) |
| Dilated jugular veins, n (%) | 217 (27%) | 2 (3%) |
| Apical beat lateralised, n (%) | 257 (32%) | 15 (25%) |
| Heart murmur, n (%) | 158 (19%) | 31 (53%) |
N/A, not applicable; BSA, body surface area; BMI, body mass index; HR, heart rate; BP, blood pressure.
The numbers (n = )/(n = ) after each patient characteristic indicate for how many adults and children data were available.
Underweight: BMI <18.5 kg/m2 for adults, or BMI for age 2 or 3 standard deviations (SD) below the WHO growth reference for children ≥5 years old, or weight for height 2 or 3 SD below the WHO growth reference for children <5 years old; Normal weight: BMI 18.5 to <25 kg/m2 for adults, or children who have no overweight nor obesity nor underweight; Overweight: BMI 25 to <30 kg/m2 for adults, or BMI for age 1 SD above the WHO growth reference for children ≥5 years old, or weight for height 2 SD above the WHO growth reference for children <5 years old; Obesity: BMI ≥30 kg/m2 for adults, or BMI for age ≥2 SD above the WHO growth reference for children ≥5 years old, or weight for height 3 SD above the WHO growth reference for children <5 years old.
Interpretation of echocardiographic findings.
| Adults (n = 815) | Children (n = 59) | |
|---|---|---|
| Normal LV size, n (%) | 93 (11%) | 29 (49%) |
| Concentric remodelling, n (%) | 161 (20%) | 10 (17%) |
| Concentric hypertrophy, n (%) | 299 (37%) | 6 (10%) |
| - Concentric hypertrophy, severe, n (%) | 191 (23%) | 5 (8%) |
| Eccentric hypertrophy, n (%) | 262 (32%) | 14 (24%) |
| - Eccentric hypertrophy, severe, n (%) | 155 (19%) | 10 (17%) |
| Normal systolic LV function (LVEF ≥54%) (n = 811)/(n = 58), n (%) | 353 (44%) | 44 (76%) |
| Mild systolic heart failure (LVEF 41–53%) (n = 811)/(n = 58), n (%) | 101 (12%) | 3 (5%) |
| Moderate systolic heart failure (LVEF 30–40%) (n = 811)/(n = 58), n (%) | 175 (22%) | 5 (9%) |
| Severe systolic heart failure (LVEF <30%) (n = 811)/(n = 58), n (%) | 182 (22%) | 6 (10%) |
| Diastolic relaxation impairment of left ventricle | ||
| - None, n (%) | 260 (32%) | 25 (42%) |
| - Grade 1, n (%) | 125 (15%) | 2 (3%) |
| - Grade 2, n (%) | 112 (14%) | 5 (8%) |
| - Grade 3, n (%) | 179 (22%) | 7 (11%) |
| - Diastolic function not determinable, n (%) | 139 (17%) | 20 (33%) |
| Diastolic relaxation impairment grade 2 or 3 and LVEF ≥50%, n (%) | 32 (4%) | 1 (2%) |
| Right ventricle, size | ||
| - Normal size, n (%) | 444 (54%) | 29 (49%) |
| - Dilated or hypertrophic, n (%) | 371 (46%) | 30 (51%) |
| Right ventricle, function | ||
| - normal, n (%) | 542 (67%) | 42 (71%) |
| - impaired, n (%) | 273 (33%) | 17 (29%) |
| Pulmonary hypertension | ||
| - no (n = 797)/(n = 58), n (%) | 464 (58%) | 34 (59%) |
| - due to left sided heart disease (i.e. elevated LAP) (n = 797)/(n = 58), n (%) | 292 (37%) | 17 (29%) |
| - due to other cause (n = 797)/(n = 58), n (%) | 41 (5%) | 7 (12%) |
| Aortic regurgitation, moderate or severe, n (%) | 58 (7%) | 1 (2%) |
| Aortic stenosis, moderate or severe, n (%) | 3 (0%) | 0 (0%) |
| Mitral regurgitation, moderate or severe, n (%) | 157 (19%) | 11 (19%) |
| Mitral stenosis, any, n (%) | 16 (2%) | 2 (3%) |
| Mitral stenosis, moderate or severe, n (%) | 13 (2%) | 2 (3%) |
| Mitral stenosis, severe, n (%) | 8 (1%) | 1 (2%) |
| Pulmonal regurgitation, moderate or severe, n (%) | 11 (1%) | 1 (2%) |
| Pulmonal stenosis, moderate or severe, n (%) | 0 (0%) | 6 (10%) |
| Tricuspid regurgitation, moderate or severe, n (%) | 101 (12%) | 11 (19%) |
LV, left ventricle; LVEF, left ventricular ejection fraction; LAP, left atrial pressure. The numbers (n = )/(n = ) indicate for how many adults and children data were available.
Causes of heart disease in 874 patients.
| Adults (n = 815) | Children (n = 59) | |
|---|---|---|
| Hypertensive HD, n (%) | 337 (41%) | 3 (5%) |
| - Hypertensive dilated cardiopathy with eccentric hypertrophy, n (%) | 76 (9%) | 1 (2%) |
| - Hypertensive HD with concentric hypertrophy, n (%) | 160 (20%) | 2 (3%) |
| Valvular HD, n (%) | 146 (18%) | 12 (20%) |
| - Rheumatic HD, n (%) | 68 (8%) | 5 (8%) |
| - Endocarditis, n (%) | 9 (1%) | 2 (3%) |
| - Valvular HD with hypertension, n (%) | 43 (5%) | 0 (0%) |
| Coronary HD, n (%) | 145 (18%) | 0 (0%) |
| - Coronary HD without hypertension, n (%) | 29 (4%) | 0 (0%) |
| - Coronary HD with hypertension, n (%) | 116 (14%) | 0 (0%) |
| Peripartum cardiomyopathy, n (%) | 56 (7%) | 0 (0%) |
| - Peripartum cardiomyopathy with hypertension, n (%) | 14 (2%) | 0 (0%) |
| Dilated cardiomyopathy, other, n (%) | 52 (6%) | 9 (15%) |
| Hypertrophic cardiomyopathy, other, n (%) | 8 (1%) | 2 (3%) |
| Endomyocardial fibrosis, n (%) | 3 (0.4%) | 1 (2%) |
| TB-pericarditis, n (%) | 16 (2%) | 5 (8%) |
| Pericarditis constrictiva, n (%) | 8 (1%) | 0 (0%) |
| Right heart failure due to pulmonal hypertension/normal LAP, n (%) | 37 (5%) | 7 (12%) |
| Arrhythmogenic right ventricular cardiomyopathy, n (%) | 2 (0.2%) | 1 (2%) |
| VSD*, n (%) | 2 (0.2%) | 6 (10%) |
| ASD, n (%) | 3 (0.4%) | 6 (10%) |
| TOF, n (%) | 0 (0%) | 6 (10%) |
| Complete AV defect, n (%) | 0 (0%) | 1 (2%) |
| PDA, n (%) | 0 (0%) | 6 (10%) |
HD, heart disease; TB, tuberculosis; LAP, left atrial pressure; VSD, ventricular septal defect; ASD, atrial septal defect; TOF, Tetralogy of Fallot; AV, atrioventricular; PDA, patent ductus arteriosus. * VSD in absence of TOF. Children with congenital heart disease: n = 20 (34%). Two children with TOF had concomitant ASD and one child with TOF had concomitant PDA. One child had VSD and ASD, one child had VSD, ASD and PDA.
Fig 1Distribution of heart diseases in adults (A) and in children (B). HD, heart disease; TB, tuberculosis.
Fig 2Medication taken before and prescribed after echocardiography in adults (A) and in children (B).